CymaBay Therapeutics Inc. (CBAY) currently has a stock price of $15.49. The stock saw a sharp increase in the last trading session, hitting a high of $16.53 after opening at $16.48. The lowest recorded price for the day was $15.82 before it closed at $15.95.
The market performance of CymaBay Therapeutics Inc. has been somewhat stable. Over the past year, the company’s stock achieved a high of $18.20 on 09/12/23, with the lowest value for the same timeframe being $3.15, recorded on 11/09/22.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
52-week price history of CBAY Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. CymaBay Therapeutics Inc.’s current trading price is -14.89% away from its 52-week high, while its distance from the 52-week low is 390.97%. The stock’s price range during this period has fluctuated between $3.15 and $18.20. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 1.55 million for the day, which was evidently lower than the average daily volume of 2.53 million over the last three months.
Financial Performance and Market Capitalization
CymaBay Therapeutics Inc. (CBAY) has experienced a quarterly rise of 84.19% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.75B and boasts a workforce of 63 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 11.34, with a change in price of +5.31. Similarly, CymaBay Therapeutics Inc. recorded 2,047,648 in trading volume during the last 100 days, posting a change of +52.27%.
CBAY Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CBAY stands at 0.92. Similarly, the long-term debt-to-equity ratio is also 0.92.
CBAY Stock Stochastic Average
CymaBay Therapeutics Inc.’s raw stochastic average for the past 50 days is currently at 63.23%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 54.17%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 64.85% and 72.58%, respectively.
CBAY Stock Price Performance Analysis
Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. Year to date metric has recorded a gain of 147.05%.However, over the last six months, we can see a weaker performance of 62.88%. Over the last 30 days, the price of CBAY has fallen by 30.39%. And in the last five days, it has fallen by -12.09%.
